• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 281

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

The Psychedelic News Feed: January 05 – 11, 2026

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

PT234 – Christopher Solomon – Salvia as a Therapist

Better Plant Appoints Branding Expert Perry Chua as Chief Creative Officer

COMPASS Pathways plc announces financial results and business highlights for fourth...

Psychedelics Research Review: February 2021

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug...

MINDCURE Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research...

MindMed Announces C$19.5 Million Bought Deal Private Placement Offering

Psychedelic Speech: How Drugs Disorganize Normal Communication Patterns

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on...

Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat

1...280281282...306Page 281 of 306

EDITOR PICKS

Australia’s Psychedelic Experiment: Progress, Pitfalls, and What Comes Next

Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and...

Op-Ed: Psychedelics in Practice: What the State Programs Are Teaching Us

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©